| CAS登錄號 | 中文名 | 英文名 | 分子結(jié)構(gòu)式 | 分子式 | 詳情 | 供應商 |
| 127785-96-0 | 6-氨甲基-6,11-二氫-5H-二苯并[b,e]氮雜卓富馬酸鹽 | 6-Aminomethyl-6,11-dihydro-5H-dibenz[b,e]azepine (E)-2-butenedioate |  | C19H20N2O4 | 詳情 | 供應商 |
| 201484-12-0 | Fmoc-D-Dab-OH | Butanoic acid,4-amino-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, (2R)-; Butanoicacid, 4-amino-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, (R)- |  | C19H20N2O4 | 詳情 | 供應商 |
| 161420-87-7 | Butanoic acid,4-amino-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, (2S)-; Butanoicacid, 4-amino-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, (S)- |  | C19H20N2O4 | 詳情 | 供應商 | |
| 122861-82-9 | Carbamic acid, cyclohexyl-,4'-nitro[1,1'-biphenyl]-4-yl ester (9CI) |  | C19H20N2O4 | 詳情 | 供應商 | |
| 10089-99-3 | Phthalazine,1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; Phthalazine,6,7-dimethoxy-1-veratryl- (6CI,7CI); 3-Azapapaverine |  | C19H20N2O4 | 詳情 | 供應商 | |
| 10405-71-7 | Pentanoic acid,4-(benzoylamino)-5-oxo-5-[(phenylmethyl)amino]-; Glutaramicacid, 4-benzamido-N-benzyl-, DL- (8CI); Glutaramic acid, 4-benzamido-N-benzyl- |  | C19H20N2O4 | 詳情 | 供應商 | |
| 5761-59-1 | Quinoxaline,6,7-dimethoxy-2-[2-(4-methoxyphenyl)ethoxy]-; Quinoxaline,6,7-dimethoxy-2-[(p-methoxyphenethyl)oxy]- (7CI,8CI) |  | C19H20N2O4 | 詳情 | 供應商 | |
| 22158-71-0 | 1H-Isoindole-1,3(2H)-dione,2-[3-[(2,5-dimethoxyphenyl)amino]propyl]-; Phthalimide,N-[3-(2,5-dimethoxyanilino)propyl]- (8CI); NSC 215998 |  | C19H20N2O4 | 詳情 | 供應商 | |
| 128022-68-4 | 1H-3-Benzazepin-7-ol,5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-8-nitro-, (5S)-; 1H-3-Benzazepin-7-ol,5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-8-nitro-, (S)-; CEE03-310; NNC 01-0687; NNC 687; NO 687 |  | C19H20N2O4 | 詳情 | 供應商 | |
| 61356-03-4 | 1H-Isoindole-1,3(2H)-dione,3a,4,7,7a-tetrahydro-2-[4-(4-morpholinylcarbonyl)phenyl]-; Morpholine,4-[4-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-2H-isoindol-2-yl)benzoyl]- (9CI) |  | C19H20N2O4 | 詳情 | 供應商 | |
| 63937-39-3 | 1,3-Dioxolo[4,5-g]isoquinoline,5,6,7,8-tetrahydro-6-methyl-5-[2-(4-nitrophenyl)ethyl]-; 1,3-Dioxolo[4,5-g]isoquinoline,5,6,7,8-tetrahydro-6-methyl-5-(p-nitrophenethyl)- (7CI) |  | C19H20N2O4 | 詳情 | 供應商 | |
| 142979-78-0 | 2,4-Imidazolidinedione,5,5-bis[(phenylmethoxy)methyl]- |  | C19H20N2O4 | 詳情 | 供應商 | |
| 1242-28-0 | 3,5-Pyrazolidinedione,4-butyl-1,2-bis(3-hydroxyphenyl)-; 3,5-Pyrazolidinedione,4-butyl-1,2-bis(m-hydroxyphenyl)- (6CI,7CI,8CI); 1,2-Bis(m-hydroxyphenyl)-3,5-dioxo-4-butylpyrazolidine |  | C19H20N2O4 | 詳情 | 供應商 | |
| 63466-99-9 | 9,10-Anthracenedione,1-[(2-hydroxyethyl)amino]-4-[(2-methoxyethyl)amino]- |  | C19H20N2O4 | 詳情 | 供應商 | |
| 80012-79-9 | 6-氨甲基-6,11-二氫-5H-二苯并[b,e]氮雜卓富馬酸鹽 | Epinastine hydrochloride interMediate product; 鹽酸依匹斯汀中間體 | 無 | C19H20N2O4 | 詳情 | 供應商 |
| 1206102-09-1 | 德羅特韋中間體 | (4R,12aS)-7-(benzyloxy)-4-Methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione; (4R,12aS)-7-(benzyloxy)-4-Methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione; Dolutegravir interMediate | 無 | C19H20N2O4 | 詳情 | 供應商 |